“By April, Lilly, with help from the U.S. National Institutes of Health, had narrowed AbCellera’s original 500 antibodies to 20 that lock onto particular sites on the spikes. After more testing, Lilly expects to select three or four for human trials that could begin as early as July.”
Read full coverage on Bloomberg Business Week.